Therapy Type: Immunotherapy (passive) (timeline)
Target Type: Amyloid-Related (timeline)
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Phase 1)
Company: Eli Lilly & Co.
LY3372993 is an investigational therapeutic of undisclosed mechanism. Details of the clinical trials listing, and Lilly's fall 2018 company pipeline, suggest it may be an antibody directed against amyloid β.
In October 2018, Lilly listed a phase 1 trial comparing LY3372993 to placebo in a total of 100 healthy adults and people with MCI due to Alzheimer's disease or mild-to-moderate AD. The study will deliver intravenous infusions of single, or multiple escalating doses, of LY3372993. It will assess adverse events, LY3372993 exposure in blood, and its ability to affect brain amyloid as measured by florbetapir PET. This study is set to run at 8 U.S. centers, from November 2018 until October 2020.
For all trials of LY3372993, see clinicaltrials.gov.
Last Updated: 09 Nov 2018
No Available Further Reading